Retatrutide is a triple receptor agonist targeting GLP-1, GIP, and glucagon receptors, whereas semaglutide targets GLP-1 only and tirzepatide targets GLP-1 and GIP
Its a hormone your body naturally makes in response to food
Additional subgroup analyses excluded trials using oral semaglutide and short-acting GLP-1RAs, as well as trials with study populations least comparable to SURPASS-CVOT
Given the shortage of endocrinologists and the demand for diabetes-related care, there is a strong need for additional training, with an emphasis on comprehensive diabetes management, for primary care and internal medicine providers [38]
Our mission is to support your health journey with professional care, advanced therapies, and a commitment to your well-being
The choice of administration frequency should align with specific research endpoints rather than defaulting to daily dosing as standard practice